Study of Evobrutinib in Participants With RMS

Stopped Following analysis of open label extension (OLE) data from RMS phase 2 study (MS200527- 0086), it was determined that a change in active comparator warranted in phase 3 RMS comprised of trial MS200527-0074. Consequently, this trial terminated early.

Conditions

• Relapsing-remitting Multiple Sclerosis

Interventions

• DRUG: Evobrutinib
• DRUG: Avonex®
• DRUG: Avonex® matched Placebo
• DRUG: Evobrutinib matched Placebo

Sponsor

EMD Serono Research & Development Institute, Inc.

Collaborators

• [object Object]